56 Examples of monthly newsletter from Clinical 31.05.18 01.06.18 12.6.18 56 Clinical Newsletter Aug 17 – Governance Team 56 Clinical Newsletter June 17 – 57 Outcome of enhanced prescribing audit being 31.05.18 04.06.18 7.6.18 57 Enhanced Audit Dr xxxx. – undertaken by Prescribing Lead. Supplementary 7.6.18 7.6.18 8.6.18 7.6.18 57 Prescribing statement – Please confirm that the allegation that triggered the 12.6.18 57a Email from Prescribing Lead – enhanced audit was due to the co-codamol “16 incident” or was there an allegation regarding something else especially controlled drugs? 58 Examples of Derek Witt’s Briefings’ for 31.05.18 01.06.18 01.06.18 58 Briefing 10/11 March ‘Friday – South East London 58 Briefing 30th March 2nd April – – 58 Briefing 26/28 May – 59 Information re incidents and complaints, staff 5.6.18 13.6.18 12.6.18 59 Email with graphs re complaints – concerns, compliments for south east area showing and incidents increase, with comparative data for last 12 months with themes. 60 Please provide categories used for themes and 5.6.18 13.6.18 12.6.18 60 Complaints Domain Assessment – complaints. Tool 60 - Complaints and Compliments Policy 61 Describe the process for the production, review and 5.6.18 12.6.18 21.6.18 61 Corporate governance policy – approval of all corporate (non-clinical) policies, review file note including whose responsibility this is, and the Revised to governance route for approval. 20.6.18 62 In particular, can you advise who is responsible for 5.6.18 12.6.18 No response received. reviewing and approving the Whistleblowing Policy and when this was last reviewed. Revised to 20.6.18 Further context from TC emailed to SK 12.6.18 On the website we see a version that was dated to expire in august 2017 (and this is still
56 Examples of monthly newsletter from Clinical Governance Team 31.05.18 01.06.18 12.6.18 56 – Clinical Newsletter Aug 17 56 – Clinical Newsletter June 17 57 Outcome of enhanced prescribing audit being undertaken by Prescribing Lead. Supplementary 7.6.18 Please confirm that the allegation that triggered the enhanced audit was due to the “16 co-codamol incident” or was there an allegation regarding something else especially controlled drugs? 31.05.18 7.6.18 04.06.18 8.6.18 7.6.18 7.6.18 12.6.18 57 – Enhanced Audit Dr xxxx. 57 – Prescribing statement 57a – Email from Prescribing Lead 58 Examples of Derek Witt’s ‘Friday Briefings’ for South East London 31.05.18 01.06.18 01.06.18 58 – Briefing 10/11 March 58 – Briefing 30th March – 2nd April 58 – Briefing 26/28 May 59 Information re incidents and complaints, staff concerns, compliments for south east area showing increase, with comparative data for last 12 months with themes. 5.6.18 13.6.18 12.6.18 59 – Email with graphs re complaints and incidents 60 Please provide categories used for themes and complaints. 5.6.18 13.6.18 12.6.18 60 – Complaints Domain Assessment Tool 60 - Complaints and Compliments Policy 61 Describe the process for the production, review and approval of all corporate (non-clinical) policies, including whose responsibility this is, and the governance route for approval. 5.6.18 12.6.18 Revised to 20.6.18 21.6.18 61 – Corporate governance policy review file note 62 In particular, can you advise who is responsible for reviewing and approving the Whistleblowing Policy and when this was last reviewed. Further context from TC emailed to SK 12.6.18 On the website we see a version that was dated to expire in august 2017 (and this is still 5.6.18 12.6.18 Revised to 20.6.18 No response received.